Reaction Biology Announces New Epigenetic Production Facilities
News Apr 26, 2012
"The new facility expands our space by over 50%, and gives us the ability to greatly expand our production of epigenetic related proteins," remarked Dr. Haiching Ma, RBC Chief Technology Officer. "We will be able to accelerate growth of our list of available targets, and add space for new collaborations."
RBC simultaneously announced that it has expanded its available list of methyltransferase and related proteins to 27, and is continuing to add more. A number of the proteins are exclusive to RBC and cannot be found elsewhere. RBC now offers 25 HMT/DNMT's, including all of the human members of the important MLL/SET1 family of multi-protein complexes, along with 11 HDAC's, 4 SIRT's, 7 HAT's, and 12 DUB's.
The field of epigenetics is rapidly becoming the new focus of the drug-discovery and pharmaceutical industry. Epigenetic targets modulate gene expression, and have been indicated in a wide variety of diseases and conditions including cancer, inflammation, metabolic and neuropsychiatric diseases.
"The ability to selectively control gene expression is a holy grail for drug researchers. Drugs that successfully inhibit HMT or DNMT targets could be hugely effective," said Dr. Konrad Howitz, RBC Director of Epigenetics. "With the largest panel of such targets and proprietary high-quality proteins, we believe RBC could play a central role in this new research."
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018